Chlamydia Treatment
For uncomplicated chlamydial infections, treat with either azithromycin 1 g orally as a single dose OR doxycycline 100 mg orally twice daily for 7 days—both are equally effective first-line options with 97-98% cure rates. 1
First-Line Treatment Regimens
The CDC guidelines establish two co-equal recommended regimens 1:
- Azithromycin 1 g orally as a single dose
- Doxycycline 100 mg orally twice daily for 7 days
Both achieve microbial cure rates of 97-98% and have equivalent efficacy and tolerability 1. Choose azithromycin when compliance with a 7-day regimen is questionable, or when directly observed therapy is needed 1. Doxycycline costs less and has no higher risk for adverse events 1.
Practical Considerations for Choosing Between First-Line Options
- Azithromycin advantages: Single-dose directly observed therapy, better for populations with erratic healthcare-seeking behavior or poor compliance 1
- Doxycycline advantages: Lower cost, longer track record of safety and efficacy 1
- Dispense medications on-site and directly observe the first dose to maximize compliance 1
Alternative Regimens (When First-Line Options Cannot Be Used)
If neither azithromycin nor doxycycline can be used 1:
- Erythromycin base 500 mg orally four times daily for 7 days
- Erythromycin ethylsuccinate 800 mg orally four times daily for 7 days
- Ofloxacin 300 mg orally twice daily for 7 days
- Levofloxacin 500 mg orally once daily for 7 days
Important caveat: Erythromycin is less efficacious than azithromycin or doxycycline due to frequent gastrointestinal side effects that discourage compliance 1. Fluoroquinolones are more expensive and offer no dosing advantage 1.
Treatment in Pregnancy
Doxycycline and fluoroquinolones (ofloxacin, levofloxacin) are absolutely contraindicated in pregnancy 2.
Recommended Regimens for Pregnant Women 2:
- Erythromycin base 500 mg orally four times daily for 7 days
- Amoxicillin 500 mg orally three times daily for 7 days
Alternative Regimens for Pregnant Women 2:
- Erythromycin base 250 mg orally four times daily for 14 days
- Erythromycin ethylsuccinate 800 mg orally four times daily for 7 days
- Erythromycin ethylsuccinate 400 mg orally four times daily for 14 days
- Azithromycin 1 g orally as a single dose
Critical note: Erythromycin estolate is contraindicated during pregnancy due to drug-related hepatotoxicity 2. While earlier guidelines expressed caution about azithromycin in pregnancy 3, more recent evidence supports its safety and effectiveness 2, 4.
All pregnant women must have repeat testing (preferably by culture) 3 weeks after completing therapy because these regimens may not be highly efficacious and erythromycin's side effects often discourage compliance 2.
Critical Management Points
Sexual Abstinence Requirements
Patients must abstain from sexual intercourse for 7 days after single-dose therapy OR until completion of a 7-day regimen 1. Additionally, abstinence must continue until all sex partners are treated to minimize reinfection risk 1.
Partner Management
- Evaluate and treat sex partners who had sexual contact within 60 days preceding symptom onset or diagnosis 1, 2
- Treat the most recent sex partner even if contact was >60 days before diagnosis 1, 2
- Consider expedited partner therapy (EPT) by providing treatment or prescription directly to the patient for their partner 4
Follow-Up Testing
Test-of-cure is NOT recommended for non-pregnant patients treated with azithromycin or doxycycline unless compliance is questionable, symptoms persist, or reinfection is suspected 1. Testing <3 weeks after treatment can yield false-positive results due to continued presence of dead organisms 1.
However, retest all women approximately 3 months after treatment because repeat infections confer elevated risk for PID and complications 1. The majority of post-treatment infections result from reinfection, not treatment failure 1.
Special Populations
HIV-Infected Patients
Treat HIV-positive patients with the same regimens as HIV-negative patients 3, 2, 3.
Coinfection with Gonorrhea
Presumptive treatment for chlamydia is appropriate for all patients being treated for gonorrhea due to high coinfection rates 1.
Common Pitfalls to Avoid
- Do not use fluoroquinolones in pregnancy or patients <18 years old 1
- Do not use erythromycin estolate in pregnancy (hepatotoxicity risk) 2
- Do not test for cure <3 weeks after treatment (false-positive risk with NAATs) 1
- Do not forget to screen and treat sex partners (high reinfection rates) 1
- Do not skip retesting women at 3 months (elevated PID risk with repeat infections) 1